Tirzepatide's approval rests on two major, named trial programs, SURPASS for diabetes and SURMOUNT for weight management, and understanding their basic structure gives useful context for how the drug's approved claims were actually established.
The SURPASS Program
The SURPASS trials evaluated tirzepatide specifically in people with type 2 diabetes, comparing it against placebo and against other established diabetes medications across multiple trials in the program, measuring outcomes including HbA1c (a measure of average blood sugar control) reduction and body weight change as secondary findings. Across this program, tirzepatide showed meaningful blood sugar improvements, generally comparing favorably to the other treatments it was tested against.
The SURMOUNT Program
The SURMOUNT trials extended testing to people with obesity or overweight, with or without diabetes, specifically evaluating weight management outcomes over roughly 72 weeks. This program reported substantial average weight loss compared to placebo across its dose range, findings that directly supported tirzepatide's separate FDA approval for chronic weight management under the Zepbound brand name.
Why Two Separate Programs Were Needed
Diabetes and weight management are distinct FDA-approved indications, each requiring its own dedicated trial program demonstrating safety and efficacy for that specific population and outcome, even though it's the same underlying drug. This is a good illustration of how specific and rigorous the approval process is, an approval for one use doesn't automatically extend to another.
Reading Trial Results With Context
As with any trial, individual results varied considerably around the reported averages, some participants lost much more weight than the average, others much less, and side effect discontinuation rates are also part of the full picture, not just the topline efficacy numbers.
The Bottom Line
The SURPASS and SURMOUNT programs represent exactly the kind of large, multi-trial, peer-reviewed evidence base described throughout this site's research guides, a meaningful contrast to the single small studies or animal-only data behind many other peptides discussed elsewhere on this site.
How These Trials Compared Against Competitor Drugs
Several SURPASS trials specifically included head-to-head comparisons against other established diabetes medications, including insulin and other GLP-1 drugs, rather than placebo alone, a stronger trial design that directly demonstrates comparative effectiveness against existing treatment options rather than only showing tirzepatide outperforms doing nothing, a distinction that matters for clinicians deciding between actual treatment alternatives.
Where to Read the Original Trial Publications
The primary results from both the SURPASS and SURMOUNT trial programs were published in major peer-reviewed medical journals and are indexed on PubMed under each trial's specific name, allowing anyone interested to read the original data and methodology directly rather than relying solely on secondary summaries, including the one provided in this article.